Prof. Dongwen Wang 王东文
Chief Physician, Professor
Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions:Head of Urology
Checked against a public report (检索 2026-11-15). Positions change; the hospital's website is the final word.
Clinical focus: Diagnosis and treatment of urinary system tumors and complex urological conditions. Application of minimally invasive urologic surgery and clinical urodynamics techniques.
Dr. Wang is a Professor and Chief Physician serving as Vice President and Director of Urology at the First Hospital of Shanxi Medical University. A doctoral supervisor, Dr. Wang has received national honors including the Wu Jieping Medical Award. Research includes over 200 publications, multiple patents, and leadership in numerous funded projects.
Professional roles
- Standing Committee Member, Urology Branch, Chinese Medical Association (CUA)
- Vice Chair, Prostate Health Advisory Committee, Asian Andrology Association (AAA)
- Standing Committee Member, Urology Professional Committee, Chinese Medical Doctor Association
- Deputy Editor-in-Chief, Chinese Journal of Endourology (Electronic Edition)
Name order: in Chinese the family name comes first (Wang Dongwen). Papers usually list the name as Dongwen Wang or Wang D.
Selected publications
47 papers on PubMed matched by name and affiliation; 29 as first or senior author since 2016. Most recent first- or senior-author papers:
- iScience, 2026 (senior author): Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth. PubMed 41704753
- Theranostics, 2026 (senior author): PSMA-targeted fluorescent probe for NIR-II imaging in prostate cancer intraoperative navigation and tumor margin mapping. PubMed 41799210
- Life Sci, 2026 (senior author): Loss of PINCH2 leads to myogenic urinary retention in mice. PubMed 41352709
- Front Immunol, 2025 (senior author): Prostate-specific membrane antigen targeted organic semiconducting polymer nanoparticles for enhanced photothermal therapy of prostate cancer. PubMed 41583450
- Sci Rep, 2025 (senior author): Prognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma. PubMed 40804289
- Int J Nanomedicine, 2025 (senior author): Enhanced NIR-II Nanoparticle Probe for PSMA-Targeted Molecular Imaging and Prostate Cancer Diagnosis. PubMed 40808713
- Exp Hematol Oncol, 2025 (senior author): Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-to-date overview based on the Global Burden of Disease 2021. PubMed 40770349
- Int Urol Nephrol, 2025 (senior author): Impact of flow rate and ratio of endoscope-sheath diameter on stone removal in flexible ureteroscopic lithotripsy: in vitro and CFD analyses insights. PubMed 39918701
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion